Keryx Biopharmaceuticals (NASDAQ:KERX) : Traders are bullish on Keryx Biopharmaceuticals (NASDAQ:KERX) as it has outperformed the S&P 500 by a wide margin of 20.32% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.27%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.62% in the last 1 week, and is up 22.26% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -26.10% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $10.51 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $6.20 and the 200 Day Moving Average price is recorded at $4.91.
The stock has recorded a 20-day Moving Average of 16.37% and the 50-Day Moving Average is 22.69%.
Keryx Biopharmaceuticals (NASDAQ:KERX): stock turned positive on Friday. Though the stock opened at $7.05, the bulls momentum made the stock top out at $7.27 level for the day. The stock recorded a low of $6.885 and closed the trading day at $7.25, in the green by 5.07%. The total traded volume for the day was 1,532,878. The stock had closed at $6.9 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Adams Brian, officer (VP and General Counsel) of Keryx Biopharmaceuticals Inc, had unloaded 660 shares at an average price of $6.66 in a transaction dated on July 5, 2016. The total value of the transaction was worth $4,396.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).